Compare Sanofi SA (SNY) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TotalEnergies SE — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while TotalEnergies SE trades at $82.04 (market cap $179.99B). The key difference: TotalEnergies SE is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | TTE | |
|---|---|---|
Market Cap | $104.83B | $179.99B |
Sector | Health | Energy |
52-Week High | $52.34 | $93.60 |
52-Week Low | $41.33 | $57.39 |
Enterprise Value | $121.32B | $214.14B |
Dividend Yield | 5.5% | 5.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
TotalEnergies (TTE) trades at $83.53, up 2.63% with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 11.99 and P/S of 0.96, with strong profitability margins. Recent Q1 2026 earnings beat expectations at $2.45 EPS, while analysts maintain a consensus Buy rating with $100 price target representing 20% upside potential.
TTE presents compelling value with conservative valuation and steady dividend payments, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Key risks include ongoing Middle East exposure and energy price volatility. The upcoming Q2 earnings report on July 23rd will be crucial for confirming the positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
